Tokyo, Japan

Sanya Akaboshi

This inventor holds 1 USPTO granted patent. Top assignee: Ohta Seiyaku Kabushiki Kaisha. Active years: 1986.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1986

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sanya Akaboshi: Innovator in Anti-inflammatory Drug Development

Introduction

Sanya Akaboshi is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-inflammatory drugs. His innovative work has led to the creation of a unique compound that addresses various dermal disorders and allergic diseases.

Latest Patents

Sanya Akaboshi holds a patent for a compound titled "6.alpha.-Methylprednisolone derivatives." This compound is characterized by a general formula that includes specific alkyl and phenyl groups. The compound exhibits a strong local anti-inflammatory effect, making it useful as a harmless external anti-inflammatory drug. It is also effective as an antiallergic drug for treating asthma and other allergic diseases. He has 1 patent to his name.

Career Highlights

Sanya Akaboshi is currently associated with Ohta Seiyaku Kabushiki Kaisha, a company known for its focus on pharmaceutical innovations. His work at the company has been instrumental in advancing the development of effective treatments for various health conditions.

Collaborations

Throughout his career, Sanya has collaborated with esteemed colleagues such as Yoshiaki Kamano and Saburo Sugai. These collaborations have further enriched his research and development efforts in the pharmaceutical field.

Conclusion

Sanya Akaboshi's contributions to the development of anti-inflammatory drugs highlight his innovative spirit and dedication to improving healthcare. His work continues to impact the treatment of dermal disorders and allergic diseases positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…